Clinical Trials Search
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4
The first purpose of this study is to test the safety of the investigational medicine at different dose levels. Investigators want to find out what effects, good and/or bad, it has on the participant's type of cancer. The second purpose of this study is to measure the levels of the investigational medicine in the participant's blood at different times. The third purpose is to see whether the investigational medicine has any effect in the control of cancer.
To evaluate the safety and pharmacokinetics of ASG-22CE in subjects with metastatic urothelial cancer. To assess the immunogenicity and anti-tumor activity of ASG-22CE in subjects with metastatic urothelial cancer.